Cat. No.: X23-10-ZQ413
JAK inhibitor Ruxolitinib phosphate, Purity ≥98%
Synonym: Ruxolitinib phosphate; 1092939-17-7; Jakafi; Jakavi; (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate; OPZELURA; Ruxolitinib (phosphate); JAK inhibitor
- MDL: MFCD18452860
- CAS Number: 1092939-17-7
- Compound CID: 25127112
Product Size
5 mg; 10 mg; 25 mg; 50 mg; 100 mg
Properties
Description
Ruxolitinib phosphate, soluble in DMSO, water and ethanol, is an available JAK small molecule inhibitor with potential antineoplastic activity. It targets JAK1, JAK2, JAK3, and Tyk2.
Molecular Formula
C17H21N6O4P
Targets
JAK1: 3.3 nM; JAK2: 2.8 nM; JAK3: 428 nM; Tyk2: 19 nM
Solubility
DMSO: 73 mg/mL (180.53 mM); Water: 26 mg/mL (64.29 mM); Ethanol: 7 mg/mL (17.31 mM)
Identity
Confirmed by NMR/HPLC/MS.
Applications
Ruxolitinib phosphate is used to study JAK1 and JAK2 selective inhibition.
Related Products
-
JAK inhibitor JAK/HDAC-IN-1, Purity ≥98%
-
JAK inhibitor 1,2,3,4,5,6-Hexabromocyclohexane, Purity ≥98%
-
JAK inhibitor Abrocitinib, Purity ≥98%
-
JAK inhibitor AZ-3, Purity ≥98%
-
JAK inhibitor AZ-960, Purity ≥98%
-
JAK inhibitor AZD1480, Purity ≥98%
Quick Links